ReviewCurrent drug delivery2026
Optimizing Transdermal Drug Delivery with Novasome Nanocarriers: A Quality by Design (QbD) Framework.
Review in Current drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Novasomal Gel for Enhanced Dermal Delivery and Antibacterial Efficacy of Cinnamic Acid.Molecules (Basel, Switzerland) · 2026Article
- Core-Sheath Nanofibers From a Modified Coaxial Electrospinning for Transdermal Delivery of Finasteride.ChemistryOpen · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A revolutionary encapsulation-based drug delivery technique called novasome technology outperforms conventional liposome systems in terms of effectiveness and efficiency. It is comprised of free fatty acid, cholesterol, and surfactant, which combine to yield better vesicle properties for medication administration. Numerous research endeavors have examined the ideal blend of surfactant types, free fatty acids, and their proportions, along with the formulation elements that might substantially impact the vesicle properties. It has been shown that novasome technology may be used to deliver various drugs, such as vaccines, niflumic acid, zolmitriptan, and terconazole. To develop the most effective novasomal formulations with significant drug loading and nano-metric form, it is important to find the appropriate ratio between core components along with critical manufacturing process determinants. Understanding the interplay between these factors requires applying Quality by Design (QBD) in combination with Design of Experiments (DoE). These may be applied for both scale-up and lab-scale applications. This manuscript includes a detailed view of novasomes and the involvement of QBD.
Indexed as
Identifiers
40197203What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.